Matching slides 303,780
Current window 211,861-211,890
Pages 10,126
Rows per page 30
Component: Titleclear collectionreset all

Component

211,861-211,890 of 303,780

filter-aware
21
The slide uses a table-like layout to present key company metrics as evidence of market readiness.Absci | Investor Presentation Deck | 27 slides · Absci
Pitch deck Investor relations Beat · ActionLoop · Before After1 hit
22
Uses quotes from partner executives to establish credibility.Absci | Investor Presentation Deck | 27 slides · Absci
Pitch deck Investor relations Beat · ActionLoop · Before After1 hit
23
The slide highlights the strategic shift towards internal asset development alongside existing partnerships, emphasizing the credibility of the team.Absci | Investor Presentation Deck | 27 slides · Absci
Pitch deck Investor relations Beat · Action1 hit
25
The slide uses a grid layout to display headshots and names, with a section for corporate logos on the bottom right.Absci | Investor Presentation Deck | 27 slides · Absci
Pitch deck Investor relations Beat · Action1 hit
26
The slide uses a growth curve (exponential) to visualize progress over time.Absci | Investor Presentation Deck | 27 slides · Absci
Pitch deck Investor relations Beat · Action1 hit
27
Absci | Investor Presentation Deck | 27 slidesAbsci | Investor Presentation Deck | 27 slides · Absci
Pitch deck Investor relations Beat · Action1 hit
01
Slide 1
Includes company logo, tagline, date, and ticker symbol.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
02
Aeglea BioTherapeutics | Investor Presentation Deck | 37 slidesAeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
03
The slide uses a list-based structure to categorize updates into clinical programs and corporate status.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
04
The slide uses a Gantt-style chart to represent clinical trial progress.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
05
Aeglea BioTherapeutics | Investor Presentation Deck | 37 slidesAeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
06
The slide uses a human silhouette to map clinical manifestations to specific body systems.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
07
Includes two testimonials from Key Opinion Leaders (KOLs) to emphasize the patient burden.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
08
The slide uses a pie chart to show patient segmentation by B6 responsiveness and a timeline/number line to show age of diagnosis, followed by key metrics on clinical complications.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
09
Includes a biological process diagram showing intracellular vs plasma metabolism.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution1 hit
10
The slide outlines a multi-part clinical trial design with specific dosing cohorts and patient eligibility requirements.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution1 hit
11
The chart displays efficacy data for a drug candidate, noting the impact of anti-drug antibodies (ADAs) on the third cohort.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution1 hit
12
Aeglea BioTherapeutics | Investor Presentation Deck | 37 slidesAeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution1 hit
13
ADA stands for Anti-Drug Antibodies.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution1 hit
14
Aeglea BioTherapeutics | Investor Presentation Deck | 37 slidesAeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
15
The slide uses a timeline-based visual to show disease progression.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Loop · Jobs To Be Done1 hit
16
The slide uses a two-column layout to contrast commercial/regulatory status with clinical trial outcomes.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Loop · Jobs To Be Done1 hit
17
The slide presents two distinct clinical metrics: a box plot for arginine levels and a bar chart for patient response rates.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Loop · Jobs To Be Done1 hit
18
Clinical trial data presentation with statistical significance markers and MCID thresholds.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Loop · Jobs To Be Done1 hit
19
The slide uses a heatmap to visualize individual patient outcomes, highlighting clinical improvement vs. worsening.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Loop · Jobs To Be Done1 hit
20
Clinical trial safety data comparing Pegzilarginase to Placebo.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Loop · Jobs To Be Done1 hit
21
Aeglea BioTherapeutics | Investor Presentation Deck | 37 slidesAeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
22
Aeglea BioTherapeutics | Investor Presentation Deck | 37 slidesAeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
24
The slide uses a biological pathway diagram to explain the mechanism of action of the drug candidate.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
26
The chart shows a clear dose-response relationship where the 10.0 mg/kg dose achieves a more significant and sustained reduction in tHcy compared to the 1.0 mg/kg dose.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit